SCHEMBL893934

SCHEMBL893934

O=[N+]([O-])c1cccc(NS(=O)(=O)c2ccccc2)c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 2/20 0.71
CA12 O43570 1/20 0.71
CA9 Q16790 1/20 0.71
POLB P06746 1/20 0.66
PGR P06401 1/20 0.65
ALDH1A1 P00352 3/20 0.63
FFAR4 Q5NUL3 1/20 0.63
CASP3 P42574 1/20 0.62
SENP8 Q96LD8 1/20 0.62
SENP7 Q9BQF6 1/20 0.62
SENP6 Q9GZR1 1/20 0.62
MEN1 O00255 3/20 0.61
KMT2A Q03164 3/20 0.61
LMNA P02545 1/20 0.61
MAPT P10636 1/20 0.61
MAPK1 P28482 1/20 0.61
SMN1; SMN2 Q16637 1/20 0.61
CRHBP P24387 1/20 0.59
CRHR2 Q13324 1/20 0.59
PKM P14618 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4101284 0.91 PGR (0.78) CA2CA12CA9PGRALDH1A1
SCHEMBL1471804 0.89 PGR (0.79) CA2CA12CA9POLBPGR
SCHEMBL27888184 0.88 HTR6 (0.68) CA2CA12CA9POLBPGR
SCHEMBL27927882 0.88 POLB (0.63) CA2CA12CA9POLBALDH1A1
SCHEMBL7336569 0.87 CA2 (0.71) CA2CA12CA9POLBPGR
SCHEMBL1472101 0.87 MEN1 (0.72) CA2CA12CA9POLBPGR
SCHEMBL12111855 0.86 CA12 (0.70) CA2CA12CA9POLBPGR
SCHEMBL16431026 0.85 PGR (0.64) CA2POLBPGRALDH1A1CASP3
SCHEMBL2242888 0.83 CA2 (1.00) CA2CA12CA9ALDH1A1MEN1
SCHEMBL15043011 0.82 ALDH1A1 (0.66) CA2PGRALDH1A1CASP3SENP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12427798-B2 Heat-sensitive recording composition NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2025-09-30 US disclosed
US-20250001788-A1 HEAT-SENSITIVE RECORDING COMPOSITION NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2025-01-02 US disclosed
EP-4442467-A1 THERMAL RECORDING COMPOSITION Nippon Kayaku Kabushiki Kaisha (JP) 2024-10-09 EP disclosed
EP-4442468-A1 HEAT-SENSITIVE RECORDING COMPOSITION Nippon Kayaku Kabushiki Kaisha (JP) 2024-10-09 EP disclosed
US-20240326501-A1 HEAT-SENSITIVE RECORDING COMPOSITION NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2024-10-03 US disclosed
CN-112533967-B Oil-in-water droplet type emulsion of active energy ray-curable resin composition and thermosensitive recording material 日本化药株式会社 2023-09-15 CN disclosed
WO-2023100900-A1 THERMAL RECORDING COMPOSITION 日本化薬株式会社 2023-06-08 WO disclosed
WO-2023100902-A1 HEAT-SENSITIVE RECORDING COMPOSITION 日本化薬株式会社 2023-06-08 WO disclosed
US-11643396-B2 BRD4-kinase inhibitors as cancer therapeutics H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2023-05-09 US disclosed
US-11612604-B2 Methods of treating cancer with PLK4 inhibitors LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (CH) 2023-03-28 US disclosed
US-6133315-A ADMINISTERING TO TREAT PANCREATITIS, THROMBOSIS, ISCHEMIA, STROKE, RESTENOSIS, EMPHYSEMA OR INFLAMMATION IN A MAMMAL; COMPOUNDS SUCH AS 2-CHLOROBENZENESULFONIC ACID 3-(3-AMIDINOPROPOXY)-5-METHYLPHENYL ESTER HYDROCHLORIDE 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2000-10-17 US disclosed
US-6034127-A CARDIOVASCULAR DISORDERS; RESPIRATORY SYSTEM DISORDERS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2000-03-07 US disclosed
EP-0859607-A4 GUANIDINO PROTEASE INHIBITORS DIMENSIONAL PHARM INC (US) 1999-05-06 EP disclosed
EP-0883405-A4 AMIDINO PROTEASE INHIBITORS DIMENSIONAL PHARM INC (US) 1999-04-28 EP disclosed
EP-0883405-A1 AMIDINO PROTEASE INHIBITORS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 1998-12-16 EP disclosed
EP-0859607-A1 GUANIDINO PROTEASE INHIBITORS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 1998-08-26 EP disclosed
US-5792769-A POTENT ANTICOAGULANT, ANTIINFLAMMATORY AGENT; TREATMENT/PROPHYLAXIS OF RESPIRATORY SYSTEM DISORDERS, VASCULAR SYSTEM DISORDERS, ANTITUMOR AGENTS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 1998-08-11 US disclosed
WO-1997024135-A1 AMIDINO PROTEASE INHIBITORS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 1997-07-10 WO disclosed
WO-1997011693-A1 GUANIDINO PROTEASE INHIBITORS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 1997-04-03 WO disclosed
US-4025614-A Substituted 2H-pyran-2,6 (3H)-dione derivatives useful in treatment of allergic reactions SMITHKLINE CORPORATION (US) 1977-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11612604-B2 Methods of treating cancer with PLK4 inhibitors PLK4, PLK2, PLK3 CA2 3588/4885CA12 4369/4885CA9 3385/4885
US-11643396-B2 BRD4-kinase inhibitors as cancer therapeutics BRD4, BICRA, BRDT CA2 4824/4885CA12 4724/4885CA9 4585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.